Cart
0

Immunoglobulin Market by Application (Hypogammaglobulinemia, Chronic Inflammatory Demyelinating Polyneuropathy, Immunodeficiency Disease, Myasthenia Gravis, Multifocal Motor Neuropathy, Idiopathic Thrombocytopenic Purpura, Inflammatory Myopathies, Specific Antibody Deficiency, Guillain-Barre Syndrome, and Others), Product Type (IgG, IgA, IgM, IgE, and IgD), and by Mode of Delivery (Intravenous and Subcutaneous): Global Opportunity Analysis and Industry Forecast, 2018 - 2025

Get 20% Free Customization In This Report
LI_172586
Pages: 220
Nov 2018 | 2718 Views
 
Author's : Onkar Sumant and Kavita Joshi
Tables: 133
Charts: 47
 

Immunoglobulin Market Overview:

Immunoglobulin, also referred to as antibody is a protein produced by plasma cells and other lymphocytes. It is complex entity that exerts its immunomodulatory effect on different components of the immune system. It is obtained from blood through the process of fractionation and is purified for therapeutic and non-therapeutic applications. Different classes of immunoglobulin, IgG, IgA, IgD, IgE, and IgM, are used for the treatment of various immunological and neurological diseases. These immunoglobulins are administered through intravenous and subcutaneous modes of delivery.

The major factors that fuel the market growth during the forecast period include increase in geriatric population & number of hemophilic patients, improved immunoglobulin production owing to the emergence of advanced technologies, and enhanced purification techniques (with better plasma yield). Furthermore, surge in prevalence diseases such as chronic inflammatory demyelinating polyneuropathy (CIDP), hypogammaglobulinemia & others are expected to boost the market growth. However, stringent government regulations toward immunoglobulin products and high risk of side effects owing to the use of immunoglobulin are expected to hamper the growth of the market.

Get more information on this report: Request Sample Pages

Application segment review

Based on application, the immunoglobulin market is divided into hypogammaglobulinemia, chronic inflammatory demyelinating polyneuropathy, immunodeficiency diseases, myasthenia gravis, multifocal motor neuropathy, idiopathic thrombocytopenic purpura, inflammatory myopathies, specific antibody deficiency, Guillain-Barre syndrome, and others. The hypogammaglobulinemia segment was the highest contributor to the market in 2017 and is anticipated to maintain its dominance throughout the forecast period. This is attributed to the significant increase in prevalence of hypogammaglobulinemia disorder across the globe over the years. For instance, hypogammaglobulinemia is the most common chronic immune defect in patients with lymphoproliferative disorders (LPDs). Its incidence rate is ~2 per 100,000 population yearly, globally.

Get more information on this report: Request Sample Pages

Mode of delivery segment review

Based on mode of delivery, the immunoglobulin market is classified into intravenous and subcutaneous. The intravenous segment accounted for the highest revenue in 2017 and is expected to maintain its dominance throughout the forecast period. High bioavailability of immunoglobulins and rapid absorption rate offered by intravenous mode of delivery are the factors that supplement the growth of the intravenous mode of delivery immunoglobulin market.

Get more information on this report: Request Sample Pages

Region segment review

Based on region, the immunoglobulin market is analyzed across North America, Europe, Asia-Pacific, and LAMEA. North America is the largest contributor toward the global market, followed by Asia-Pacific. These regions collectively occupy almost 75% of the global market revenue. Presence of the largest plasma production facilities and high adoption rate in the developed countries majorly boost the market growth. However, Asia-Pacific is projected to register the highest growth rate from 2018 to 2025.

The report provides extensive competitive analysis and profiles of key market players that includes Baxter international Inc., CSL Ltd., Grifols S.A, Octapharma AG, Kedrion Biopharma Inc., LFB group, Biotest AG, China Biologics Products, Inc., Shire (Baxalta), and Bayer Healthcare.

Other players in the value chain include Hualan Biological Engineering Inc., Omrix Biopharmaceuticals Ltd., Behring GmbH, Shanghai RAAS Blood Products Co., Ltd., Option Care Enterprises, Inc., ADMA Biologics, Inc., and BioScrip, Inc.

Key Benefits for Immunoglobulin Market:

  • The study provides an in-depth analysis of the global allergy treatment market with the current trends and future estimations to elucidate the imminent investment pockets.

  • A comprehensive analysis of the factors that drive and restrict the market growth is provided.

  • A comprehensive quantitative analysis of the industry is provided from 2018 to 2025 to assist stakeholders to capitalize on the prevailing market opportunities.

  • An extensive analysis of the key segments of the industry helps understand the trends in the global allergy treatment market.

  • Key players and their strategies are provided to understand the competitive outlook of the industry.

Immunoglobulin Key Market Segments:

By Application

  • Hypogammaglobulinemia

  • Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

  • Immunodeficiency Disease

  • Myasthenia Gravis

  • Multifocal Motor Neuropathy

  • Idiopathic Thrombocytopenic Purpura (ITP)

  • Inflammatory Myopathies

  • Specific Antibody Deficiency

  • Guillain‐Barré Syndrome

  • Others

By Product

  • IgG

  • IgA

  • IgM

  • IgE

  • IgD

By Mode of Delivery

  • Intravenous

    • 5% Concentration

    • 10% Concentration

    • Others

  • Subcutaneous

    • 16.5% Concentration

    • 20% Concentration

    • Others

By Region

  • North America

    • U.S.

    • Canada

    • Mexico

  • Europe

    • Germany

    • UK

    • France

    • Italy

    • Austria

    • Russia

    • Rest of Europe

  • Asia-Pacific

    • Japan

    • China

    • Australia

    • India

    • Rest of Asia-Pacific

  • LAMEA

    • Brazil

    • Turkey

    • Argentina

    • Saudi Arabia

    • Rest of LAMEA

 

Chapter: 1: INTRODUCTION

1.1. Report description
1.2. Key benefits for stakeholders
1.3. Key market segments
1.4. Research methodology

1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools & models

Chapter: 2: EXECUTIVE SUMMARY

2.1. CXO perspective

Chapter: 3: MARKET OVERVIEW

3.1. Market definition and scope
3.2. Key findings

3.2.1. Top investment pockets
3.2.2. Top Winning Strategies

3.3. Porters five forces analysis
3.4. Market share analysis, 2017
3.5. Market dynamics

3.5.1. Drivers

3.5.1.1. Rise in prevalence of immunodeficiency diseases
3.5.1.2. Increase in adoption of immunoglobulin
3.5.1.3. Increase in incidence of bleeding disorders
3.5.1.4. Surge in geriatric population

3.5.2. Restraints

3.5.2.1. Stringent government regulations
3.5.2.2. High cost of therapy

3.5.3. Opportunities

3.5.3.1. Opportunities in emerging economies
3.5.3.2. Development of cost-effective therapeutics through large-scale production

Chapter: 4: IMMUNOGLOBULIN MARKET, BY APPLICATION

4.1. Overview

4.1.1. Market size and forecast

4.2. HYPOGAMMAGLOBULINEMIA

4.2.1. Market size and forecast

4.3. Chronic Inflammatory demyelinating polyneuropathy (CIDP)

4.3.1. Market size and forecast

4.4. Idiopathic thrombocytopenic purpura

4.4.1. Market size and forecast

4.5. Myasthenia Gravis

4.5.1. Market size and forecast

4.6. MULTIFOCAL MOTOR NEUROPATHY

4.6.1. Market size and forecast

4.7. Idiopathic thrombocytopenic purpura (ITP)

4.7.1. Market size and forecast

4.8. INFLAMMATORY MYOPATHIES

4.8.1. Market size and forecast

4.9. Specific antibody deficiency

4.9.1. Market size and forecast

4.10. Guillain-Barre syndrome

4.10.1. Market size and forecast

4.11. Others

4.11.1. Market size and forecast

Chapter: 5: IMMUNOGLOBULIN MARKET, BY PRODUCT

5.1. Overview

5.1.1. IGG
5.1.2. Key market trends
5.1.3. Clinical interpretations
5.1.4. IGA
5.1.5. Key Market Trends
5.1.6. Clinical interpretation
5.1.7. IGM
5.1.8. Key Market Trends
5.1.9. Clinical interpretation
5.1.10. IGE
5.1.11. Key Market Trend
5.1.12. Clinical interpretation
5.1.13. IGD
5.1.14. Key Market Trends
5.1.15. Clinical interpretation

Chapter: 6: IMMUNOGLOBULIN MARKET, BY MODE OF DELIVERY

6.1. Overview

6.1.1. Market size and forecast

6.2. INTRAVENOUS MODE OF DELIVERY

6.2.1. Key Market Trends
6.2.2. Market size and forecast

6.2.2.1. 5% concentration

6.2.3. Market size and forecast

6.2.3.1. 10% Concentration

6.2.4. Market size and forecast

6.2.4.1. Other Concentrations

6.2.5. Market size and forecast

6.3. SUBCUTANEOUS MODE OF DELIVERY

6.3.1. Key Market Trends
6.3.2. Market size and forecast

6.3.2.1. 5% Concentration

6.3.3. Market size and forecast

6.3.3.1. 16.5% Concentration

6.3.4. Market size and forecast

6.3.4.1. 20% Concentration

6.3.5. Market size and forecast

6.3.5.1. Other Concentration

6.3.6. Market size and forecast

Chapter: 7: IMMUNOGLOBULIN MARKET, BY REGION

7.1. Overview

7.1.1. Market size and forecast

7.2. North America

7.2.1. Key trends and opportunities
7.2.2. North America market size & forecast, by country
7.2.3. North America market size & forecast, by application
7.2.4. North America market size & forecast, by mode of delivery

7.2.4.1. U.S. market size & forecast
7.2.4.2. Canada market size & forecast
7.2.4.3. Mexico market size & forecast

7.3. Europe

7.3.1. Key trends and opportunities
7.3.2. Europe market size & forecast for immunoglobulin market, by country
7.3.3. Europe market size & forecast, by application
7.3.4. Europe market size & forecast, by mode of delivery

7.3.4.1. Germany market size & forecast
7.3.4.2. France market size & forecast
7.3.4.3. UK market size & forecast
7.3.4.4. Italy market size & forecast
7.3.4.5. Spain market size & forecast
7.3.4.6. Russia market size & forecast
7.3.4.7. Rest of Europe market size & forecast

7.4. Asia-Pacific

7.4.1. Key trends and opportunities
7.4.2. Asia-Pacific market size & forecast, by country
7.4.3. Asia-Pacific market size & forecast, by application
7.4.4. Asia-Pacific market size & forecast, by mode of delivery

7.4.4.1. Japan market size & forecast
7.4.4.2. China market size & forecast
7.4.4.3. India market size & forecast
7.4.4.4. Australia market size & forecast
7.4.4.5. South Korea market size & forecast
7.4.4.6. Taiwan market size & forecast
7.4.4.7. Rest of Asia-Pacific market size & forecast

7.5. LAMEA

7.5.1. Key trends and opportunities
7.5.2. LAMEA market size & forecast, by country
7.5.3. LAMEA market size & forecast, by application
7.5.4. LAMEA market size & forecast, by mode of delivery

7.5.4.1. Brazil market size & forecast
7.5.4.2. South Africa market size & forecast
7.5.4.3. Saudi Arabia market size & forecast
7.5.4.4. Argentina market size & forecast
7.5.4.5. Rest of LAMEA market size & forecast

Chapter: 8: COMPANY PROFILES

8.1. Baxter International Inc.

8.1.1. Company overview
8.1.2. Company snapshot
8.1.3. Operating business segments
8.1.4. Product portfolio
8.1.5. Business performance
8.1.6. Key strategic moves and developments

8.2. Biotest AG

8.2.1. Company overview
8.2.2. Company snapshot
8.2.3. Operating business segments
8.2.4. Product portfolio
8.2.5. Business performance

8.3. CSL Limited

8.3.1. Company overview
8.3.2. Company snapshot
8.3.3. Operating business segments
8.3.4. Product portfolio
8.3.5. Business performance
8.3.6. Key strategic moves and developments

8.4. Grifols S.A.

8.4.1. Company overview
8.4.2. Company snapshot
8.4.3. Operating business segments
8.4.4. Product portfolio
8.4.5. Business performance
8.4.6. Key strategic moves and developments

8.5. LFB SA (LFB Biotechnologies SAS)

8.5.1. Company overview
8.5.2. Company snapshot
8.5.3. Operating business segments
8.5.4. Product portfolio
8.5.5. Business performance

8.6. Octapharma AG

8.6.1. Company overview
8.6.2. Company snapshot
8.6.3. Operating business segments
8.6.4. Product portfolio
8.6.5. Business performance

8.7. Bayer AG

8.7.1. Company overview
8.7.2. Company snapshot
8.7.3. Operating business segments
8.7.4. Business performance
8.7.5. Key strategic moves and developments

8.8. Kedrion Biopharma Inc.

8.8.1. Company overview
8.8.2. Company snapshot
8.8.3. Operating business segments
8.8.4. Product portfolio
8.8.5. Business performance

8.9. Shire Plc.(Baxalta)

8.9.1. Company overview
8.9.2. Company snapshot
8.9.3. Operating business segments
8.9.4. Product portfolio
8.9.5. Business performance
8.9.6. Key strategic moves and developments

8.10. China Biologic Products, Inc.

8.10.1. Company overview
8.10.2. Company snapshot
8.10.3. Operating business segments
8.10.4. Product portfolio
8.10.5. Business performance

LIST OF TABLES

TABLE 01. GLOBAL IMMUNOGLOBULIN MARKET, BY APPLICATION, 20172025 ($MILLION)
TABLE 02. GLOBAL IMMUNOGLOBULIN MARKET, BY APPLICATION, 20172025 (KILOGRAM)
TABLE 03. GLOBAL IMMUNOGLOBULIN MARKET, FOR HYPOGAMMAGLOBULINEMIA, BY REGION, 20172025 ($MILLION)
TABLE 04. GLOBAL IMMUNOGLOBULIN MARKET, FOR CIPD, BY REGION, 20172025 ($MILLION)
TABLE 05. GLOBAL IMMUNOGLOBULIN MARKET, FOR CIPD, BY REGION, 20172025 (KILOGRAMS)
TABLE 06. GLOBAL IMMUNOGLOBULIN MARKET, FOR IDIOPATHIC THROMBOCYTOPENIC PURPURA BY REGION, 20172025 ($MILLION)
TABLE 07. GLOBAL IMMUNOGLOBULIN MARKET, FOR IDIOPATHIC THROMBOCYTOPENIC PURPURA BY REGION, 20172025 (KILOGRAMS)
TABLE 08. GLOBAL IMMUNOGLOBULIN MARKET, FOR MYASTHENIA GRAVIS (MG), BY REGION, 20172025 ($MILLION)
TABLE 09. GLOBAL IMMUNOGLOBULIN MARKET, FOR MYASTHENIA GRAVIS (MG), BY REGION, 20172025 (KILOGRAMS)
TABLE 10. GLOBAL IMMUNOGLOBULIN MARKET, FOR MULTIFOCAL MOTOR NEUROPATHY, BY REGION, 20172025 ($MILLION)
TABLE 11. GLOBAL IMMUNOGLOBULIN MARKET, FOR MULTIFOCAL MOTOR NEUROPATHY, BY REGION, 20172025 (KILOGRAMS)
TABLE 12. GLOBAL IMMUNOGLOBULIN MARKET, FOR IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP), BY REGION, 20172025 ($MILLION)
TABLE 13. GLOBAL IMMUNOGLOBULIN MARKET, FOR IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP), BY REGION, 20172025 (KILOGRAMS)
TABLE 14. GLOBAL IMMUNOGLOBULIN MARKET, FOR INFLAMMATORY MYOPATHY, BY REGION, 20172025 ($MILLION)
TABLE 15. GLOBAL IMMUNOGLOBULIN MARKET, FOR INFLAMMATORY MYOPATHY, BY REGION, 20172025 (KILOGRAMS)
TABLE 16. GLOBAL IMMUNOGLOBULIN MARKET, FOR SPECIFIC ANTIBODY DEFICIENCY (SAD), BY REGION, 20172025 ($MILLION)
TABLE 17. GLOBAL IMMUNOGLOBULIN MARKET, FOR SPECIFIC ANTIBODY DEFICIENCY (SAD), BY REGION, 20172025 (KILOGRAMS)
TABLE 18. GLOBAL IMMUNOGLOBULIN MARKET, FOR GUILLAIN-BARRE SYNDROME, BY REGION, 20172025 ($MILLION)
TABLE 19. GLOBAL IMMUNOGLOBULIN MARKET, FOR GUILLAIN-BARRE SYNDROME), BY REGION, 20172025 (KILOGRAMS)
TABLE 20. GLOBAL IMMUNOGLOBULIN MARKET, FOR OTHERS, BY REGION, 20172025 ($MILLION)
TABLE 21. GLOBAL IMMUNOGLOBULIN MARKET, FOR OTHERS, BY REGION, 20172025 (KILOGRAMS)
TABLE 22. GLOBAL IMMUNOGLOBULIN MARKET, BY MODE OF DELIVERY, 20172025 ($MILLION)
TABLE 23. GLOBAL IMMUNOGLOBULIN MARKET, BY MODE OF DELIVERY, 20172025 (KILOGRAMS)
TABLE 24. IMMUNOGLOBULIN MARKET, FOR INTRAVENOUS, BY REGION, 20172025 ($MILLION)
TABLE 25. IMMUNOGLOBULIN MARKET, FOR INTRAVENOUS, BY REGION, 20172025 (KILOGRAMS)
TABLE 26. IMMUNOGLOBULIN MARKET, FOR 5% CONCENTRATION, BY REGION, 20172025 ($MILLION)
TABLE 27. IMMUNOGLOBULIN MARKET, FOR 10% CONCENTRATION, 20172025 ($MILLION)
TABLE 28. GLOBAL IMMUNOGLOBULIN MARKET, FOR OTHER CONCENTRATIONS, 20172025 ($MILLION)
TABLE 29. IMMUNOGLOBULIN MARKET, FOR SUBCUTANEOUS MODE OF DELIVERY, BY REGION, 20172025 ($MILLION)
TABLE 30. IMMUNOGLOBULIN MARKET, FOR SUBCUTANEOUS MODE OF DELIVERY, BY REGION, 20172025 (KILOGRAMS)
TABLE 31. GLOBAL IMMUNOGLOBULIN MARKET, BY REGION, 20172025 ($MILLION)
TABLE 32. GLOBAL IMMUNOGLOBULIN MARKET, BY REGION, 20172025 (KILOGRAMS)
TABLE 33. NORTH AMERICA IMMUNOGLOBULIN MARKET, BY COUNTRY, 20172025 ($MILLION)
TABLE 34. NORTH AMERICA IMMUNOGLOBULIN MARKET, BY COUNTRY, 20172025 (KILOGRAMS)
TABLE 35. NORTH AMERICA IMMUNOGLOBULIN MARKET, BY APPLICATION, 20172025 ($MILLION)
TABLE 36. NORTH AMERICA IMMUNOGLOBULIN MARKET, BY TARGET AREA, 20172025 ($MILLION)
TABLE 37. EUROPE IMMUNOGLOBULIN MARKET, BY COUNTRY, 20172025 ($MILLION)
TABLE 38. EUROPE IMMUNOGLOBULIN MARKET, BY APPLICATION, 20172025 ($MILLION)
TABLE 39. EUROPE IMMUNOGLOBULIN MARKET, BY MODE OF DELIVERY, 20172025 ($MILLION)
TABLE 40. ASIA-PACIFIC IMMUNOGLOBULIN MARKET, BY COUNTRY, 20172025 ($MILLION)
TABLE 41. ASIA-PACIFIC IMMUNOGLOBULIN MARKET, BY APPLICATION, 20172025 ($MILLION)
TABLE 42. ASIA-PACIFIC IMMUNOGLOBULIN MARKET, BY MODE OF DELIVERY, 20172025 ($MILLION)
TABLE 43. LAMEA IMMUNOGLOBULIN MARKET, BY COUNTRY, 20172025 ($MILLION)
TABLE 44. LAMEA IMMUNOGLOBULIN MARKET, BY APPLICATION, 20172025 ($MILLION)
TABLE 45. LAMEA IMMUNOGLOBULIN MARKET, BY MODE OF DELIVERY, 20172025 ($MILLION)
TABLE 46. BAXTER: COMPANY SNAPSHOT
TABLE 47. BAXTER: OPERATING SEGMENTS
TABLE 48. BAXTER: PRODUCT PORTFOLIO
TABLE 49. BIOTEST: COMPANY SNAPSHOT
TABLE 50. BIOTEST: OPERATING SEGMENTS
TABLE 51. BIOTEST: OPERATING SEGMENT
TABLE 52. CSL: COMPANY SNAPSHOT
TABLE 53. CSL: PRODUCT SEGMENTS
TABLE 54. CSL: PRODUCT PORTFOLIO
TABLE 55. GRIFOLS: COMPANY SNAPSHOT
TABLE 56. GRIFOLS: OPERATING SEGMENTS
TABLE 57. GRIFOLS: PRODUCT PORTFOLIO
TABLE 58. LFB: COMPANY SNAPSHOT
TABLE 59. LFB: PRODUCT SEGMENTS
TABLE 60. LFB: PRODUCT PORTFOLIO
TABLE 61. OCTAPHARMA: COMPANY SNAPSHOT
TABLE 62. OCTAPHARMA: PRODUCT SEGMENTS
TABLE 63. OCTAPHARMA: PRODUCT PORTFOLIO
TABLE 64. BAYER: COMPANY SNAPSHOT
TABLE 65. BAYER: OPERATING SEGMENTS
TABLE 66. KEDRION: COMPANY SNAPSHOT
TABLE 67. KEDRION: PRODUCT PORTFOLIO
TABLE 68. SHIRE: COMPANY SNAPSHOT
TABLE 69. SHIRE: PRODUCT PORTFOLIO
TABLE 70. CHINA BIOLOGIC COMPANY SNAPSHOT
TABLE 71. CHINA BIOLOGIC PRODUCT PORTFOLIO

LIST OF FIGURES

FIGURE 01. IMMUNOGLOBULIN MARKET SEGMENTATION
FIGURE 02. TOP WINNING STRATEGIES, BY YEAR, 2015-2018*
FIGURE 03. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2015-2018* (%)
FIGURE 04. TOP WINNING STRATEGIES, BY COMPANY, 2015-2018*
FIGURE 05. LOW BARGAINING POWER OF SUPPLIERS
FIGURE 06. HIGH BARGAINING POWER OF BUYERS
FIGURE 07. HIGH THREAT OF SUBSTITUTION
FIGURE 08. HIGH THREAT OF NEW ENTRANTS
FIGURE 09. HIGH COMPETITIVE RIVALRY
FIGURE 10. MARKET SHARE ANALYSIS, 2017
FIGURE 11. GLOBAL IMMUNOGLOBULIN MARKET: DRIVERS, RESTRAINTS, AND OPPORTUNITIES
FIGURE 01. U.S. IMMUNOGLOBULIN MARKET, 2017-2025 ($ MILLION)
FIGURE 02. CANADA IMMUNOGLOBULIN MARKET, 2017-2025 ($ MILLION)
FIGURE 03. MEXICO IMMUNOGLOBULIN MARKET, 2017-2025 ($ MILLION)
FIGURE 04. GERMANY IMMUNOGLOBULIN MARKET, 2017-2025 ($ MILLION)

FIGURE 05. FRANCE IMMUNOGLOBULIN MARKET, 2017-2025 ($ MILLION)
FIGURE 06. UK IMMUNOGLOBULIN MARKET, 2017-2025 ($ MILLION)
FIGURE 07. ITALY IMMUNOGLOBULIN MARKET, 2017-2025 ($ MILLION)

FIGURE 08. SPAIN IMMUNOGLOBULIN MARKET, 2017-2025 ($ MILLION)
FIGURE 09. RUSSIA IMMUNOGLOBULIN MARKET, 2017-2025 ($ MILLION)
FIGURE 10. REST OF EUROPE IMMUNOGLOBULIN MARKET, 2017-2025 ($ MILLION)

FIGURE 11. JAPAN IMMUNOGLOBULIN MARKET, 2017-2025 ($ MILLION)
FIGURE 12. CHINA IMMUNOGLOBULIN MARKET, 2017-2025 ($ MILLION)
FIGURE 13. INDIA IMMUNOGLOBULIN MARKET, 2017-2025 ($ MILLION)
FIGURE 14. AUSTRALIA IMMUNOGLOBULIN MARKET, 2017-2025 ($ MILLION)
FIGURE 15. AUSTRALIA IMMUNOGLOBULIN MARKET, 2017-2025 ($ MILLION)
FIGURE 16. TAIWAN IMMUNOGLOBULIN MARKET, 2017-2025 ($ MILLION)

FIGURE 17. REST OF ASIA-PACIFIC IMMUNOGLOBULIN MARKET, 2017-2025 ($ MILLION)
FIGURE 18. BRAZIL IMMUNOGLOBULIN MARKET, 2017-2025 ($ MILLION)
FIGURE 19. SOUTH AFRICA IMMUNOGLOBULIN MARKET, 2017-2025 ($ MILLION)
FIGURE 20. SAUDI ARABIA IMMUNOGLOBULIN MARKET, 20172025 ($MILLION)
FIGURE 21. ARGENTINA IMMUNOGLOBULIN MARKET, 20172025 ($MILLION)
FIGURE 22. REST OF LAMEA IMMUNOGLOBULIN MARKET, 20172025 ($MILLION)

FIGURE 23. BAXTER: NET SALES, 20152017 ($MILLION)
FIGURE 24. BAXTER: REVENUE SHARE BY SEGMENT, 2017 (%)
FIGURE 25. BAXTER: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
FIGURE 26. BIOTEST: NET SALES, 20152017 ($MILLION)
FIGURE 27. BIOTEST: REVENUE SHARE BY SEGMENT, 2017 (%)
FIGURE 28. BIOTEST: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
FIGURE 29. CSL: NET SALES, 20152017 ($MILLION)
FIGURE 30. CSL: REVENUE SHARE BY SEGMENT, 2017 (%)
FIGURE 31. CSL: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
FIGURE 32. GRIFOLS: NET SALES, 20152017 ($MILLION)
FIGURE 33. GRIFOLS: REVENUE SHARE BY SEGMENT, 2017 (%)
FIGURE 34. GRIFOLS: REVENUE SHARE BY GEOGRAPHY, 2017 (%)

FIGURE 35. LFB: NET SALES, 20142016 ($MILLION)
FIGURE 36. LFB: REVENUE SHARE BY PRODUCT SEGMENT, 2016 (%)
FIGURE 37. LFB: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
FIGURE 38. OCTAPHARMA: NET SALES, 20152017 ($MILLION)
FIGURE 39. BAYER: NET SALES, 20152017 ($MILLION)
FIGURE 40. BAYER: REVENUE SHARE BY SEGMENT, 2017 (%)
FIGURE 41. BAYER: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
FIGURE 42. KEDRION: NET SALES, 20152017 ($MILLION)
FIGURE 43. KEDRION: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
FIGURE 44. SHIRE: NET SALES, 20152017 ($MILLION)
FIGURE 45. SHIRE: REVENUE SHARE BY PRODUCT, 2017 (%)
FIGURE 46. SHIRE: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
FIGURE 47. CHINA BIOLOGIC NET SALES, 20152017 ($MILLION)

 

 

The immunoglobulin products gained significant attention in the recent years due to their efficacy in the treatment of immune diseases. Immunoglobulin is considered to be the most effective treatment for hypogammaglobulinemia, CIDP, and immunodeficiency diseases, which are the largest immunoglobulin consuming indications in the global immunoglobulin market, owing to the large patient population and unavailability of effective alternative treatments.

Presence of limited number of plasma donors hampers the market growth. To resolve this, immunoglobulin producers have appealed to the local government for favorable pricing policy in selective regions of the market and they have successfully gained support from government authorities. Therefore, the average price of immunoglobulin is projected to remain relatively stable during the forecast period.

Moreover, the substantial development in technology involved in plasma production and purification is expected to significantly increase the immunoglobulin production. In addition, the key players have decided to strengthen their research activities for the development of therapies for rare diseases through immunoglobulin products, which are anticipated to provide growth opportunities in the immunoglobulin market.

The administration of immunoglobulin is the highest in North America, owing to the increase in adoption of immunoglobulin products, high awareness regarding the benefits of using immunoglobulin therapies among the healthcare providers, and increase in disposable income among patients. Although the use of immunoglobulin in LAMEA is low, the adoption rate is expected to increase due to rise in disposable income, surge in healthcare expenditure, and government initiative to enhance the healthcare departments. These factors contribute toward the market growth.

 

 

PURCHASE OPTIONS

* Taxes/Fees, If applicable will be
added during checkout. All prices in USD.

Reach out to us

Call us on
( U.S. - Canada toll free )
+1-800-792-5285,    Int'l : +1-503-894-6022
Drop us an email at
help@alliedmarketresearch.com

Send Enquiry
 

Request Sample

Request Customization

Request sample

OR

Purchase Full Report of
Immunoglobulin Market

  • Online Only
  • $3456
  • Online cloud Access only
  • Restricted Print, copy, paste,download
  • Read Only
  • 20% free customization (Pre-Sale)
  •   Free quartery industry update
  •   Free report update (Within 180 days)
  •   Subscription Model Sign In
  • Data Pack
  • $3840
  • Restricted to one authorized users
  • One print only
  • Available in Excel
  • 20% free customization (Pre-Sale)
  •   Free quartery industry update
  •   Free report update (Within 180 days)
  •   Subscription Model Sign In
  • Single User
  • $5370
  • Restricted to one authorized users
  • One print only
  • Available in Excel & PDF
  • 20% free customization (Pre-Sale)
  •   Free quartery industry update
  •   Free report update (Within 180 days)
  •   Subscription Model Sign In
  • Five User
  • $6450
  • Limited to 5 authorized users
  • Print Upto Five Copies
  • Available in Excel & PDF
  • 20% free customization (Pre-Sale)
  •   Free quartery industry update
  •   Free report update (Within 180 days)
  •   Subscription Model Sign In
  • Enterprise
    License/PDF

  • $8995
  • Unlimited within company/enterprise
  • Unlimited within company/enterprise
  • Available in Excel & PDF
  • 20% free customization (Pre-Sale)
  •   Free quartery industry update
  •   Free report update (Within 180 days)
  •   Subscription Model Sign In

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

 

HAVE QUESTIONS?
SPEAK WITH ANALYST

 
 

FREQUENTLY ASKED
QUESTIONS?

 
 

DID YOU MISS ANYTHING?
DO YOU HAVE SPECIFIC REQUIREMENTS?

 
 
 

Why Allied Market Research

 

Infallible Methodology

To ensure high level data integrity, accurate analysis and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

 
 

Featured Reports

 
 

Featured Readings

 

Get Fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

 
Get Industry Data Alerts
 

Access reports on all emerging
market of Life Sciences on Knowledge Tree Platform
Free Demo